Sectors

GTBP
GT Biopharma, Inc.
0.35
1 x 0.32
1 x 0.39
bid
ask
-
0.01
1.70%
09:25 AM
timesize
Ytd-55.15%
1y-82.30%
0.35
day range
0.36
0.26
52 week range
2.29
Open0.36Prev Close0.36Low0.35High0.36Mkt Cap3.81M
Vol41.79KAvg Vol1.54MEPS-3.71P/E-0.10Forward P/E-0.26
Beta0.84Short Ratio0.71Inst. Own67.52%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1850-d Avg0.43200-d Avg0.551yr Est11.00

GTBP News

Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
globenewswire.com
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet

Issued on behalf of GT Biopharma, Inc. (Nasdaq: GTBP) A clinical-stage immuno-oncology company has m

12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives
globenewswire.com
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Techno

Increased integration of artificial intelligence–based tools across the discovery and engineering of

The $13 Million Company Teaching the Immune System to Hunt Cancer
prnewswire.com
The $13 Million Company Teaching the Immune System to Hunt Cancer

/PRNewswire/ -- USA News Group Market Commentary - Start with the number that makes everyone do a do

B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
prnewswire.com
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic

/PRNewswire/ -- USA News Group News Commentary - For more than two decades, B7-H3 sat on the shortli

GT Biopharma Reports First Quarter 2026 Financial Results
globenewswire.com
GT Biopharma Reports First Quarter 2026 Financial Results

Phase 1 trial evaluating GTB-3650 TriKE ® remains ongoing, with additional updates anticipated in 2H

12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors
globenewswire.com
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Ki

GTB-5550 is now the 3rd TriKE ® to enter the clinic and an expansion into a broader solid tumor oppo

EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types
benzinga.com
EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Typ

GT Biopharma Inc. (NASDAQ:GTBP) on Thursday dosed the first patient on a Phase 1 dose-escalation bas

12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session

12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session

12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

Head to Head Contrast: Cogent Biosciences (NASDAQ:COGT) versus GT Biopharma (NASDAQ:GTBP)
defenseworld.net
Head to Head Contrast: Cogent Biosciences (NASDAQ:COGT) versus GT Biopharma (NASDAQ:GTBP)

Cogent Biosciences (NASDAQ: COGT - Get Free Report) and GT Biopharma (NASDAQ: GTBP - Get Free Report

GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know
zacks.com
GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know

GT Biopharma (GTBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about th

GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
zacks.com
GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

GT Biopharma (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after lo

GT Biopharma to Participate in the 38th Annual Roth Conference
globenewswire.com
GT Biopharma to Participate in the 38th Annual Roth Conference

SAN FRANCISCO, CALIFORNIA, March 11, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NA

GT Biopharma Reports Full Year 2025 Financial Results
globenewswire.com
GT Biopharma Reports Full Year 2025 Financial Results

Phase 1 trial evaluating GTB-3650 TriKE ® continues to actively enroll, with the next update anticip

GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference
globenewswire.com
GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference

SAN FRANCISCO, CALIFORNIA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NAS

12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3
globenewswire.com
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriK

GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026 Phase 1 protocol allows

12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session

12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session

GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers
globenewswire.com
GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell

GT Biopharma targets a portion of the estimated $362 billion global solid tumor market Preliminary,

EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment
benzinga.com
EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment

GT Biopharma Inc. (NASDAQ: GTBP) on Thursday said it submitted an investigational new drug (IND) app

Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
globenewswire.com
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge

VANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - The

Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030
prnewswire.com
Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030

Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC , Dec. 19, 2025 /PRNewswire/ --  USA News Group

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
prnewswire.com
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

/PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia eliminat

12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials
accessnewswire.com
GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials

NAPLES, FL / ACCESS Newswire / November 19, 2025 / Patients battling aggressive blood cancers face l

12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session

12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session

benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session

Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarke

benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

benzinga.com
Stocks That Hit 52-Week Lows On Friday

  On Friday, 1043 companies hit new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Monday

    On Monday, 721 companies achieved new lows for the year.

benzinga.com
Stocks That Hit 52-Week Highs On Monday

    Monday's morning session saw 253 companies set new 52-week highs.